Showing results (131-140 of 172) with videos related to

Sort By:
Pageof 18
Skeletal Radiology|March 21, 2026
Soft tissue reporting and data system (soft tissue-RADS): framework for radiologists specializing in imaging of musculoskeletal tumors and tumor-like lesionsAvneesh Chhabra, Mark D Murphey, Mahad Rehman, et al.
The Oncologist|August 21, 2013
β-Catenin mutation status and outcomes in sporadic desmoid tumorsJohn T Mullen, Thomas F DeLaney, Andrew E Rosenberg, et al.
Journal of Orthopaedic Research : Official Publication of the Orthopaedic Research Society|April 17, 2012
Establishment and characterization of a novel chordoma cell line: CH22Xianzhe Liu, Gunnlager Petur Nielsen, Andrew E Rosenberg, et al.
Lancet (London, England)|February 15, 2016
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trialPatrick Schöffski, Sant Chawla, Robert G Maki, et al.
The American Journal of Surgical Pathology|June 11, 2021
Clinical Utility of Anchored Multiplex Solid Fusion Assay for Diagnosis of Bone and Soft Tissue TumorsIvan Chebib, Martin S Taylor, Valentina Nardi, et al.
Plos Genetics|December 2, 2008
Genetic analysis of human traits in vitro: drug response and gene expression in lymphoblastoid cell linesEdwin Choy, Roman Yelensky, Sasha Bonakdar, et al.
Communications Biology|March 9, 2022
Genome-wide DNA methylation patterns reveal clinically relevant predictive and prognostic subtypes in human osteosarcomaChristopher E Lietz, Erik T Newman, Andrew D Kelly, et al.
Scientific Reports|March 12, 2020
MicroRNA-mRNA networks define translatable molecular outcome phenotypes in osteosarcomaChristopher E Lietz, Cassandra Garbutt, William T Barry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2026
A Phase 2 Study of the Eribulin in Patients with Metastatic Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)Gregory M Cote, Mason Aberoumand, Edwin Choy, et al.
Medrxiv : the Preprint Server for Health Sciences|July 1, 2024
A dynamic microRNA profile that tracks a chemotherapy resistance phenotype in osteosarcoma. Implications for novel therapeuticsChristopher E Lietz, Erik T Newman, Andrew D Kelly, et al.
Pageof 18